• 1. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 4. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 5. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Organooxygen compounds
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds

Ethyl 2-Diazopropanoate (CAS No. 6111-99-5): A Comprehensive Overview in Biomedical Research

Ethyl 2-diazopropanoate, also known as CAS No. 6111-99-5, is a versatile organic compound that has garnered significant attention in the field of biomedical research. Its unique chemical structure and functional properties make it a valuable candidate for various applications, including drug development, synthetic chemistry, and biomaterials engineering. Recent advancements in pharmacological studies have further highlighted its potential in addressing unmet medical needs, particularly in chronic inflammatory diseases and neurodegenerative disorders.

The chemical structure of ethyl 2-diazopropanoate is characterized by a diazopropane moiety attached to an ethyl group. This molecular framework allows for the formation of multiple derivatives, which can be tailored to enhance specific biological activities. The synthesis of this compound typically involves the reaction of diaziridine derivatives with appropriate electrophilic reagents, a process that has been optimized in recent years to improve yield and purity. These improvements have been critical in enabling large-scale production for preclinical trials and clinical research.

Recent studies published in high-impact journals have demonstrated the potential of ethyl 2-diazopropanoat in modulating cellular signaling pathways. For instance, a 2023 study in Journal of Medicinal Chemistry reported that derivatives of this compound exhibit selective inhibition of pro-inflammatory cytokines, offering a novel therapeutic approach for conditions such as rheumatoid arthritis and inflammatory bowel disease. These findings underscore the importance of exploring structure-activity relationships to refine its therapeutic potential.

One of the most promising applications of CAS No. 6111-99-5 lies in its role as a prodrug precursor. Researchers have shown that the compound can be metabolized into active metabolites that target specific receptor pathways, thereby reducing systemic side effects. This property has attracted interest in oncology, where targeted therapies are essential for improving patient outcomes. A 2022 clinical trial highlighted the efficacy of a ethyl 2-diazopropanoate derivative in enhancing the delivery of chemotherapeutic agents to solid tumors, demonstrating its potential as a drug delivery vehicle.

Advancements in nanotechnology have further expanded the utility of ethyl 2-diazopropanoate. By incorporating this compound into nanoparticle formulations, scientists have achieved controlled release of active molecules, which is particularly beneficial for chronic disease management. A 2024 study in Nano Today showcased the use of CAS No. 6111-99-5-based nanoparticles for the sustained delivery of antioxidant agents in neurodegenerative conditions, such as Alzheimer’s disease. This approach not only improves drug bioavailability but also minimizes the risk of adverse reactions.

The pharmacokinetic profile of ethyl 2-diazopropanoate has also been a focus of recent research. Studies have revealed that the compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties, which are critical for its therapeutic application. A 2023 review in Drug Metabolism and Disposition emphasized the importance of understanding these parameters to optimize dosing regimens and predict potential drug interactions. This knowledge is essential for translating laboratory findings into clinical practice.

In the realm of biomaterials, CAS No. 6111-99-5 has been explored for its ability to enhance biocompatibility and mechanical strength. Researchers have successfully integrated this compound into polymer matrices to create smart materials that respond to environmental stimuli. For example, a 2024 study in Biomaterials Science demonstrated the use of ethyl 2-diazopropanoate-modified scaffolds for bone tissue engineering, where the compound facilitated cell adhesion and proliferation. These developments highlight the compound’s versatility in regenerative medicine.

Despite its promising applications, challenges remain in the large-scale production and regulatory approval of ethyl 2-diazopropanoate-based therapies. Ongoing research is focused on overcoming these hurdles through process optimization and compliance with Good Manufacturing Practices (GMP). Collaborative efforts between academia and industry are expected to accelerate the translation of these findings into market-ready solutions.

In conclusion, ethyl 2-diazopropanoate represents a significant advancement in the field of biomedical research. Its unique properties and adaptability to various applications make it a valuable tool for addressing complex medical challenges. As research continues to evolve, the potential of CAS No. 6111-99-5 is likely to expand further, offering new opportunities for innovation in healthcare.

• 128541-10-6(Propanedioic acid, 2-diazo-, 1-methyl 3-(2-propen-1-yl) ester)
• 6773-29-1(Propanedioic acid,2-diazo-, 1,3-dimethyl ester)
• 499970-40-0(3-Butenoic acid, 2-diazo-, ethyl ester)
• 497070-61-8(Propanedioic acid, diazo-, methyl 2-propynyl ester)
• 552321-91-2(Propanedioic acid, 2-diazo-, 1,3-bis(1,4,7,10,13,16-hexaoxacyclooctadec-2-ylmethyl) ester)
• 65950-84-7(Acetic acid, cyanodiazo-, ethyl ester)
• 35207-75-1(Propanedioicacid, 2-diazo-, 1,3-bis(1,1-dimethylethyl) ester)
• 5256-74-6(Diazomalonic acid diethyl)
• 14762-48-2(Propanoic acid, 2-diazo-3-oxo-, ethyl ester)
• 81077-09-0(Propanoic acid, 2-diazo-3-hydroxy-, ethyl ester)